clinical trial · NCT03901755
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
Swedish Orphan Biovitrum·—·completed·n = 151
Hemophilia BAlprolix
brief summary
Alprolix (rFIXFc) is a recombinant extended half-life coagulation factor product. The purpose of this non-interventional study is to describe the real-world usage and effectiveness of Alprolix in the on-demand and prophylactic treatment of haemophilia B.
started
Sep 12, 2019
primary completion
Mar 12, 2024
completion
Mar 12, 2024
last updated
Sep 29, 2025
official title
A 24-month Prospective, Non-interventional, International, Multicentre Study to Describe the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol